An outline on the potential of health apps to drive personalized healthcare, to fuel a debate with prof Marli Huijer (filosophy and former thinker of the Netherlands). The lecture can also be viewed on www.youtube.com/watch?v=6FqbLmqmCUk.
In Dutch.
An interview on the potential and challenges of personalized medicine, published in Medisch Contact (a monthy journal for healthcare professionals). In Dutch.
2019 03-14 Health Valley Event 2019, Nijmegen, Alain van GoolAlain van Gool
Lecture on innovations in personalized healthcare using an integrated X-omics approach towards personalized diagnostics, as part of the regional ambitious TopFit program.
An interview on the potential and challenges of personalized medicine, published in Medisch Contact (a monthy journal for healthcare professionals). In Dutch.
2019 03-14 Health Valley Event 2019, Nijmegen, Alain van GoolAlain van Gool
Lecture on innovations in personalized healthcare using an integrated X-omics approach towards personalized diagnostics, as part of the regional ambitious TopFit program.
Quantified Self voor gepersonaliseerde gezondheidWessel Kraaij
*Dutch*
Presentatie voor symposium datagedreven wetenschap Adviesraad Wetenschap Technologie en Innovatie
Impact van quantified self technieken op het onderzoek naar gepersonaliseerde diagnose en prognose in relatie tot gezondheid
Presentatie gegeven door Prof. Dr. Ir. Andre Dekker, klinisch fysicus en manager Onderzoek en Onderwijs bij MAASTRO clinic op het KNMG Limburg Symposium 'Toekomst van de Zorg' op 17 mei 2018.
Big Data leveren binnen de zorg veel voordelen. De reden? Er zijn veel gegevens aanwezig. Denk aan data afkomstig uit MRI-scans, wearables en aantekeningen van artsen en verpleging. Toch wordt nog maar weinig met deze data gedaan. Zonde!
In dit webinar laten we zien wat Big Data zijn en welke voordelen ze bieden. We gaan in op zaken als: clinical intelligence, de patiënt journey, analysestrategieën en tools (bijv. supercomputer Watson). Tot slot bespreken we real-life cases.
2023-11-14 Biomarkers Europe 2023, Berlin, Alain van Gool.pdfAlain van Gool
Lecture at the Biomarkers Europe 2023 conference for an audience of pharma scientists and omics/data solution providers. I outlined several initiatives of potential interest and discussed development of our sensitive personalized clinical biomarker test for minimal residual disease monitoring in multiple myeloma.
2023-11-09 HealthRI Biobanking day_Amsterdam_Alain van Gool.pdfAlain van Gool
Examples of lessons learned in Omics-based biomarker studies from myself and colleagues in X-omics and EATRIS, for an audience of biobankers, researchers and diagnostic/clinical chemistry experts.
More Related Content
Similar to 2017 05-16 Radboud Reflects, Nijmegen, Alain van Gool
Quantified Self voor gepersonaliseerde gezondheidWessel Kraaij
*Dutch*
Presentatie voor symposium datagedreven wetenschap Adviesraad Wetenschap Technologie en Innovatie
Impact van quantified self technieken op het onderzoek naar gepersonaliseerde diagnose en prognose in relatie tot gezondheid
Presentatie gegeven door Prof. Dr. Ir. Andre Dekker, klinisch fysicus en manager Onderzoek en Onderwijs bij MAASTRO clinic op het KNMG Limburg Symposium 'Toekomst van de Zorg' op 17 mei 2018.
Big Data leveren binnen de zorg veel voordelen. De reden? Er zijn veel gegevens aanwezig. Denk aan data afkomstig uit MRI-scans, wearables en aantekeningen van artsen en verpleging. Toch wordt nog maar weinig met deze data gedaan. Zonde!
In dit webinar laten we zien wat Big Data zijn en welke voordelen ze bieden. We gaan in op zaken als: clinical intelligence, de patiënt journey, analysestrategieën en tools (bijv. supercomputer Watson). Tot slot bespreken we real-life cases.
2023-11-14 Biomarkers Europe 2023, Berlin, Alain van Gool.pdfAlain van Gool
Lecture at the Biomarkers Europe 2023 conference for an audience of pharma scientists and omics/data solution providers. I outlined several initiatives of potential interest and discussed development of our sensitive personalized clinical biomarker test for minimal residual disease monitoring in multiple myeloma.
2023-11-09 HealthRI Biobanking day_Amsterdam_Alain van Gool.pdfAlain van Gool
Examples of lessons learned in Omics-based biomarker studies from myself and colleagues in X-omics and EATRIS, for an audience of biobankers, researchers and diagnostic/clinical chemistry experts.
2023-04-20 EATRIS-Plus Summerschool, Lisbon, Alain van GoolAlain van Gool
Closing keynote lecture at the EATRIS-Plus summerschool on personalised medicine, outlining developments, opportunities, challenges and recommendations to do next in this exciting era of personalised medicine.
2022-11-23 DTL Future of data-driven life sciences, Utrecht, Alain van Gool.pdfAlain van Gool
A pitch on directions to improve experimental reproducibility, illustrated by examples of past experiences. I made the plee to move from 'Proudly invented here' to 'Proudly copyied from', to re-use each other's eperiences in successes and failures.
2022-10-12 The future of population health_Alain van Gool.pdfAlain van Gool
1) Exponential developments in omics technologies like genomics, proteomics, and metabolomics are driving more personalized approaches to healthcare.
2) Mass spectrometry methods have been developed to sensitively detect minimal residual disease in multiple myeloma patients from plasma samples, allowing for dynamic monitoring and earlier detection of relapse compared to traditional methods.
3) Large-scale multi-omics studies incorporating data from various sources can provide a more holistic view of health and disease at both the individual and population levels, supporting personalized prevention and treatment approaches.
2022-09-08 ECPM Digital Biomarkers and AI, Basel, Alain van Gool.pdfAlain van Gool
Lecture for 150 pharma professionals to outline the potentials and things-to-do with digital biomarkers, as part of a ECPM training on digitization and AI in drug development.
2022-04-14 EuroMedLab, Munich, Alain van GoolAlain van Gool
Keynote lecture at the EuroMedLab 2021 providing an audience of clinical chemists and laboratory medicine scientists with advancements of multi-omics applications in personalized healthcare, and challenges that we need to solve as translational scientists.
2021 12-10 Amalia Science Day, Nijmegen, Alain van GoolAlain van Gool
This document discusses the use of omics technologies like genomics, proteomics, and glycoproteomics in pediatric healthcare. Specifically, it describes a study that used glycoproteomics to analyze blood samples from children with febrile illness to distinguish between viral and bacterial infections. The analysis identified glycoprotein biomarkers that could accurately classify 70-80% of samples as viral or bacterial. Integrating multiple omics data through machine learning approaches may provide a more comprehensive understanding of diseases and lead to personalized diagnosis and treatment.
2021 06-14 EATRIS-Plus summer school, Alain van GoolAlain van Gool
Introductory lecture for the 100 participant summer school of the EATRIS-Plus project, outlining personalized medicine, biomarker and multi-omics strategies and use cases.
2021 03-25 11th World Clinical Biomarkers & Companion Diagnostics, Alain van ...Alain van Gool
Closing keynote of a 3-day conference on clinical biomarkers and companion diagnostics, organised by Hanson Wade, outlining the power of omics approaches in healthcare and translation of inovations to impact.
2020 09-07 European Center Pharmaceutical Medicine course Biomarkers, Basel, ...Alain van Gool
Tutorial lecture on biomarkers for pharmaceutical industry R&D professionals, outlining status, potential and challenges of biomarkers in pharma, clinic and society.
2020 08-28 SensUs Event 2020 keynote, Eindhoven, Alain van GoolAlain van Gool
Closing keynote for international students participating in the SensUs Event 2020, where they designed and created a novel sensor for drug level monitoring in epilepsy treatment. Lecture outlined innovations in biomarkers in personalized health(care).
2020 02-10 European Center Pharmaceutical Medicine course - biomarkers, Basel...Alain van Gool
This document discusses biomarkers and personalized healthcare. It begins with an overview of biomarkers in the pharmaceutical industry and how they are used from drug discovery through clinical trials. It then discusses biomarkers in academic research and healthcare, and how emerging digital biomarkers could enable personalized health monitoring. The presentation identifies some translational innovation gaps, and concludes with an outlook on how biomarkers and multi-omics approaches will continue to advance personalized diagnosis and therapies.
2019 10-14 2nd Int Congress on Precision Medicine, Munich, Alain van GoolAlain van Gool
Opening lecture at the 2nd International Congress on Precision Medicine in Munich, outlining progress in omics-based biomarkers for rare diseases, biomarker innovation gaps and multi-partner initiatives to bridge those gaps to applications. Also reviewed the highlights of our recently published Handbook of Biomarkers and Precision Medicine.
2019 09-23 COST CliniMARK summerschool, Spetses, Alain van GoolAlain van Gool
Opening lecture of the COST CliniMARK summer school 'Approaches for Biomarker Discovery and Validation'. Extensive introduction in biomarker approached used in pharmaceutical industry, academic research and clinical care, and society, combined with review of biomarker innovation gaps and outlook.
2019 06-19 Dutch association for clinical chemistry and laboratory medicine -...Alain van Gool
Sharing my views on how X-omics biomarker analyses through next gen sequencing and mass spectrometry will change the landscape of diagnostics and clinical chemistry in the near future.
4. Source: Chakma, Journal of Young Investigators, 16, 2009
Principe van ‘Personalized Medicine’
• Het juiste medicijn voor de juiste patient met juiste dosering
• = ‘Precision medicine’ of ‘Targeted medicine’
4
5. Speod cursus in moleculaire biologie
DNA, eiwit, cel, weefsel, systeem biologie
5
6. Enorme technologie intwikkeling in de laboratoria
• Next generation sequencen
• DNA, RNA
• Mass spectrometrie
• Proteins, metabolites
• Imaging
• Non invasive images, real time
500
1000
1500
2000
m/z
5 10 15 20 25 30 35 40 Time [min]
6
8. Beweging naar ‘personalized health(care)’
{Source: Barabási 2007 NEJM 357; 4}
• Mensen zijn meer dan een moleculair defect
• Verschillende networken en risico factoren
• Verschillende voorkeuren
8
9. 9
“It’s far more important to know
what person the disease has
than what disease the person
has.”
Hippocrates, 400 B.C
11. Naar een personalized data-driven GPS voor gezondheid
• Meet (biomarkers) op
achtergrond
• Alarm wanneer jij ee risico
loopt
• Adviseer wat te doen
11
27. 3 kern aspecten van personalized health(care)
‘Ik wil gezond blijven.
Zo niet, hoe wordt Ik weer gezond?’
1. Wat moet ik dan meten?
2. Hoe veel mag dat veranderen?
3. Wat moet ik dan doen?
27
28. Personalized health(care) model
Persoonlijke
interventies
Door patienten-zoals-ik
Persoonlijke grenzen
Van mensen-zoals-ik
Big
Biomarker
Data
Moleculair
Niet-moleculair
Omgeving
…
Zelfmonitoring
Aangepast van Jan van der Greef, TNO
Personal profile
Personalized health
Personalized medicine
28
Persoonlijk profiel
Ziek
Gezond